Cyclophosphamide, GVHD, GVHD prevention
Cyclophosphamide's lack of hematopoietic stem cell toxicity and its unique effects on the immune system have prompted several investigators to explore its potential for the prevention of graft-versus-host disease (GVHD). In haploidentical hematopoietic stem cell transplants, post-transplant cyclophosphamide together with standard prophylaxis reduces the incidence of GVHD to acceptable rates without the need for T cell depletion. In matched related and unrelated donor settings, cyclophosphamide alone has produced encouraging results. In particular, the low incidence of chronic GVHD is noteworthy. Here, we present a review of the current understanding of the mechanism of action of post-transplant cyclophosphamide and summarize the clinical data on its use for the prevention of GVHD.
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Al-Homsi, A. S., Roy, T. S., Cole, K., Feng, Y., & Duffner, U. (2015). Post-Transplant High-Dose Cyclophosphamide for the Prevention of Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 21(4), 604–611. https://doi.org/10.1016/j.bbmt.2014.08.014
Al-Homsi, Ahmad Samer; Roy, Tara S.; Cole, Kelli; Feng, Benjamin; and Duffner, Ulrich, "Post-Transplant High-Dose Cyclophosphamide for the Prevention of Graft-versus-Host Disease" (2014). Peer Reviewed Articles. 78.